Recent studies reported antidepressant action, both in preclinical and clinical studies, of NMDAR antagonists. Creative Biolabs has focused on psychotropic drug development for years, and with extensive experience, we are capable of providing target development services to global researchers.
Introduction to NMDAR
NMDARs are heteromeric complexes incorporating different subunits within a repertoire of three subtypes: NR1, NR2, and NR3. There are eight different NR1 subunits generated by alternative splicing from a single gene, four different NR2 subunits (A, B, C, and D) and two NR3 subunits (A and B); the NR2 and NR3 subunits are encoded by six separate genes. Expression of functional recombinant NMDARs in mammalian cells requires the co-expression of at least one NR1 and one NR2 subtype. The stoichiometry of NMDARs has not yet been established definitely, but the consensus is that NMDARs are tetramers that most often incorporate two NR1 and two NR2 subunits of the same or different subtypes. In cells expressing NR3, it is thought that this subunit co-assembles with NR1 and NR2 to form ternary NR1/NR2/NR3 tetrameric complexes.
Therapeutic Applications of NMDAR in Psychiatric Disease
NMDA receptors have received much attention over the last few decades, due to their key role in many types of neural plasticity on the one hand, and their involvement in neuronal excitotoxicity on the other hand. An important goal of much recent research is to identify clinically relevant NMDA receptor antagonists capability of preferentially blocking excitotoxic NMDA receptor activation without interfering with NMDA receptor function needed for normal synaptic transmission and plasticity. For example, dextromethorphan/bupropion is an orally administered, rapidly-acting, investigational NMDA receptor antagonist with multimodal activity.
Services at Creative Biolabs
With the rising concern about the psychiatric disorder, Creative Biolabs is committed to fully understanding the novel psychotropic target development. Based on the advanced technology platform, extensive experience, and professional Ph.D. level scientists, we are capable of providing global customers with psychotropic drug development process services.
NMDA receptor antagonists have been reported that have the potential of application in the target development of psychiatric disorders. Based on the mature technology and experts, Creative Biolabs is capable of offering a top-rated customer services to every client. If you have any other questions, please feel free to contact us.
For Research Use Only.
